FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

AI Summary

The US Food and Drug Administration is requiring GLP-1 medication labels to warn about a rare eye condition that can cause sudden, permanent blindness. The warning applies to drugs including Ozempic, Wegovy, Mounjaro, Zepbound, and Soliqua.

The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness. On Monday, the FDA announced that it is requiring all GLP-1 medications – including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as Sanofi’s Soliqua – to include information about the potential risk of nonarteritic anterior ischemic optic neuropathy, also known as NAION, on warning labels. Continue reading...